Lonza uses creative deal making and other people's money to climb to top position
Jan 1, 2007
By:
Jim Miller
The number of projects in Lonza's internal biomanufacturing pipeline grew by 40% to over 75 projects.
|
Buyers of pharmaceutical services are changing their behavior—and service providers need to change theirs, too
Oct 1, 2006
By:
Jim Miller
A major shift is occurring in the way the biopharmaceutical industry sources goods and services. Price pressures at the retail end of the value chain and a difficult fundraising environment are forcing biopharmaceutical companies to take greater control of their costs. Purchased goods and services, including contract research and manufacturing services as well as raw materials and laboratory supplies, are a major expense in most companies, so control of those purchasing decisions is coming in for special scrutiny.
|
Companies pursuing the integrated supply chain model offer clients an accelerated path from benchtop to clinic
Jul 1, 2006
By:
Jim Miller
The lack of biomanufacturer acquisitions seems surprising.
|
When it comes to biomanufacturing capacity, the rich are getting richer
Apr 1, 2006
By:
Jim Miller
Interestingly, it is companies that already have the most capacity available to them that are building even more.
|
Less capacity, more technology is the latest strategy adopted in contract biomanufacturing
Feb 1, 2006
By:
Jim Miller
Moving aggressively to implement its Vision 2010 strategy, which debuted in October 2005, DSM N.V. (Heerlen, Netherlands) announced in December 2005 that it would shut down its Montreal biomanufacturing facility in early 2006. The move doesn't signal an exit from manufacturing, however, but a change in focus; DSM will simultaneously expand its expression-technology relationship with Crucell (Leiden, the Netherlands). Both moves reflect changing circumstances in the biomanufacturing sector.
|
CROs and CMOs in Asia offer a growing array of outsourcing opportunities for motivated biopharm companies.
Sep 1, 2005
By:
Jim Miller
In addition to India and China, other Asian countries are establishing themselves as destinations for biopharma companies.
|
CROs and CMOs could face diminishing opportunities and escalating competition in the days ahead.
Jun 1, 2005
By:
Jim Miller
Avariety of forces are combining to fundamentally change the financial dynamics of the biopharmaceutical industry. The initial public offering (IPO) appears to be giving way to licensing arrangements with, and acquisitions by, major pharmaceutical companies.
|
2005 is shaping up as a big year for preclinical and clinical CROs, while contract manufacturers hope to see a reversal of a depressing four-year trend.
Feb 1, 2005
By:
Jim Miller
The contract manufacturing sector has not enjoyed the success of preclinical and clinical businesses.
|
Contract biomanufacturing competition focuses on technology, not capacity.
Aug 1, 2004
By:
Jim Miller
Technology innovations aimed at increasing yields and shortening development times can be very cost-effective, promising to reduce the need for large capital investments while getting the client into the clinic much faster.
|
|
